MedWatch

European innovation initiative puts Novo, Sanofi, and Eli Lilly in the same room

Novo Nordisk is participating in a public-private, European initiative, under which the firm has to share data with some of its biggest competition. Being a partner and a competitor can be a balancing act, according to Novo VP Matthias Müllenborn.

Matthias Müllenborn, vice president for study programs, patients and partnerships at Novo Nordisk | Photo: Ulrich Quistgaard

Novo Nordisk sees clear advantages from being part of the new public-private, European partnership, dubbed the Innovative Health Initiative (IHI), which brings the EU and the life science industry closer to each other with a budget of EUR 2.4bn.

Being a member also means sharing clinical data within the partnership, which might put the Danish pharmaceutical giant in a precarious situation, as its biggest global competitors also have seats at the table.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Analyst predicts slow start for Leo Pharma's Adtralza in UK

The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.

Further reading

Related articles

Latest news

See all jobs